Literature DB >> 10716083

Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora.

C Edlund1, G Beyer, M Hiemer-Bau, S Ziege, H Lode, C E Nord.   

Abstract

Twelve healthy male subjects age range 24-40 y participated in the investigation. The trial was divided into 2 35-d periods. The 2 treatment regimens were: (i) 1 x 400 mg moxifloxacin tablet in the morning and 1 placebo tablet in the evening for 7 d; and (ii) 1 x 500 mg clarithromycin tablet in the morning and 1 x 500 mg clarithromycin tablet in the evening for 7 d. Each subject received firstly I treatment regimen and secondly the other treatment regimen. The wash-out period was 6 weeks between the two treatment regimens. Moxifloxacin caused significant decreases of enterococci and enterobacteria during the administration period while the numbers of staphylococci, streptococci, Bacillus and Candida were not affected. No impact on peptostreptococci, lactobacilli, Veillonella, Bacteroides or fusobacteria was observed, while bifidobacteria and clostridia decreased during moxifloxacin administration. The microflora was normalized after 35 d. Clarithromycin caused significant reduction of Escherichia coli while the numbers of enterococci, Enterobacter, Citrobacter, Klebsiella and Pseudomonas increased markedly. No significant changes in the numbers of staphylococci, streptococci, Bacillus and Candida were noticed. In the anaerobic microflora bifidobacteria, lactobacilli and clostridia were suppressed, while no changes in peptostreptococci, Veillonella, Bacteroides and fusobacteria were found. The microflora was normalized in all volunteers after 35 d.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716083     DOI: 10.1080/00365540050164272

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  29 in total

1.  Frequent transmission of enterococcal strains between mechanically ventilated patients treated at an intensive care unit.

Authors:  Bodil Lund; Christina Agvald-Ohman; Anna Hultberg; Charlotta Edlund
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism.

Authors:  Cecilia Jernberg; Asa Sullivan; Charlotta Edlund; Janet K Jansson
Journal:  Appl Environ Microbiol       Date:  2005-01       Impact factor: 4.792

3.  Emergence and acquisition of fluoroquinolone-resistant gram-negative bacilli in the intestinal tracts of mice treated with fluoroquinolone antimicrobial agents.

Authors:  Michael J Pultz; Michelle M Nerandzic; Usha Stiefel; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

Review 4.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

5.  Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings.

Authors:  Gwen Duytschaever; Geert Huys; Maarten Bekaert; Linda Boulanger; Kris De Boeck; Peter Vandamme
Journal:  Appl Environ Microbiol       Date:  2011-09-16       Impact factor: 4.792

6.  Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

7.  Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study.

Authors:  Hans F Berg; Jeroen H T Tjhie; Gert-Jan Scheffer; Marcel F Peeters; Peter H J van Keulen; Jan A J W Kluytmans; Ellen E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 8.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.

Authors:  Josip Bago; Karolina Majstorović; Zeljka Belosić-Halle; Nastja Kućisec; Vinko Bakula; Monika Tomić; Petra Bago; Rosana Troskot
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-04-15       Impact factor: 3.944

10.  Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Authors:  Mamun-Ur Rashid; Staffan Rosenborg; Georgios Panagiotidis; Johan Holm; Karin Söderberg Löfdal; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.